The Liver Meeting: Vir Biotechnology presented data from programs for chronic hepatitis B and chronic hepatitis delta

blonca9
Nov 21, 2024
1 min read

Vir Chief Medical Officer Mark Eisner discusses the MARCH Phase 2 study results for hepaitis B, and Hôpital Beaujon Professor of Hepatology Tarik Asselah discusses the SOLSTICE Phase 2 study results for hepatitis delta.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

The Liver Meeting: Vir Biotechnology presented data from programs for chronic hepatitis B and chronic hepatitis delta

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight